Senior Fellow, FasterCures, and Founder, InnoThink
Bernard Munos is founder and chief apostle of InnoThink, a consultancy dedicated to bringing evidence-based innovation models to the pharmaceutical industry. Previously an advisor for corporate strategy at Eli Lilly, he has long focused on disruptive innovation in drug development and on the radical redesign of R&D.
Munos' research has been published in Nature and Science, and he has presented his findings to the National Academies, the Institute of Medicine, the President's Cancer Panel, the National Institutes of Health Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, the Council for American Medical Innovation and many others.
He received his M.B.A from Stanford University, and holds other graduate degrees in economics and animal science from the University of California, Davis and the Paris Institute of Technology for Life, Food and Environmental Sciences.